Prostate cancer (PrCa) is highly heritable; 284 variants have been identified to date that are associated with increased prostate cancer risk, yet few genes contributing to its development are known. Expression quantitative trait loci (eQTL) studies link variants with affected genes, helping to determine how these variants might regulate gene expression and may influence prostate cancer risk. In the current study, we performed eQTL analysis on 471 normal prostate epithelium samples and 249 PrCa-risk variants in 196 risk loci, utilizing RNA sequencing transcriptome data based on ENSEMBL gene definition and genome-wide variant data. We identified a total of 213 genes associated with known PrCa-risk variants, including 141 protein-coding genes...
Although genome-wide association studies (GWAS) for prostate cancer (PrCa) have identified more than...
Here we tested the hypothesis that SNPs associated with prostate cancer risk, might differentially a...
Tremendous advances in genomic capabilities, including high-throughput genotyping technology and alg...
Prostate cancer (PrCa) is highly heritable; 284 variants have been identified to date that are assoc...
Numerous Genome Wide Association (GWA) studies of large populations have provided limited biomarkers...
Genome-wide association study-identified prostate cancer risk variants explain only a relatively sma...
Genome-wide association study-identified prostate cancer risk variants explain only a relatively sma...
Prostate cancer (PC) is the most frequently diagnosed non-skin cancer in the world. Previous studies...
Genome-wide association study-identified prostate cancer risk variants explain only a relatively sma...
Genome-wide association studies (GWAS) have revolutionized the field of cancer genetics, but the cau...
Heritability is one of the strongest risk factors of prostate cancer, emphasizing the importance of ...
Many genetic variants affect disease risk by altering context-dependent gene regulation. Such varian...
<div><p>Genome-wide association studies (GWAS) have revolutionized the field of cancer genetics, but...
Although genome-wide association studies (GWAS) for prostate cancer (PrCa) have identified more than...
Genome-wide association studies (GWAS) have revolutionized the field of cancer genetics, but the cau...
Although genome-wide association studies (GWAS) for prostate cancer (PrCa) have identified more than...
Here we tested the hypothesis that SNPs associated with prostate cancer risk, might differentially a...
Tremendous advances in genomic capabilities, including high-throughput genotyping technology and alg...
Prostate cancer (PrCa) is highly heritable; 284 variants have been identified to date that are assoc...
Numerous Genome Wide Association (GWA) studies of large populations have provided limited biomarkers...
Genome-wide association study-identified prostate cancer risk variants explain only a relatively sma...
Genome-wide association study-identified prostate cancer risk variants explain only a relatively sma...
Prostate cancer (PC) is the most frequently diagnosed non-skin cancer in the world. Previous studies...
Genome-wide association study-identified prostate cancer risk variants explain only a relatively sma...
Genome-wide association studies (GWAS) have revolutionized the field of cancer genetics, but the cau...
Heritability is one of the strongest risk factors of prostate cancer, emphasizing the importance of ...
Many genetic variants affect disease risk by altering context-dependent gene regulation. Such varian...
<div><p>Genome-wide association studies (GWAS) have revolutionized the field of cancer genetics, but...
Although genome-wide association studies (GWAS) for prostate cancer (PrCa) have identified more than...
Genome-wide association studies (GWAS) have revolutionized the field of cancer genetics, but the cau...
Although genome-wide association studies (GWAS) for prostate cancer (PrCa) have identified more than...
Here we tested the hypothesis that SNPs associated with prostate cancer risk, might differentially a...
Tremendous advances in genomic capabilities, including high-throughput genotyping technology and alg...